Capricor Therapeutics Inc (NASDAQ:CAPR) Receives Consensus Recommendation of “Buy” from Analysts

Shares of Capricor Therapeutics Inc (NASDAQ:CAPR) have received an average rating of “Buy” from the six analysts that are covering the company, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a buy rating. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $34.50.

CAPR has been the subject of a number of recent research reports. HC Wainwright restated a “buy” rating and set a $77.00 target price on shares of Capricor Therapeutics in a research report on Monday, March 17th. Cantor Fitzgerald reissued an “overweight” rating and set a $30.00 price objective on shares of Capricor Therapeutics in a report on Thursday, March 20th.

Capricor Therapeutics Trading Up 8.0 %

CAPR stock opened at $9.40 on Friday. Capricor Therapeutics has a 1-year low of $3.52 and a 1-year high of $23.40. The business’s 50 day moving average is $12.95 and its 200-day moving average is $15.15. The firm has a market cap of $429.35 million, a P/E ratio of -8.87 and a beta of 4.65.

Capricor Therapeutics (NASDAQ:CAPR) last issued its quarterly earnings results on Wednesday, March 19th. The biotechnology company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.15. Capricor Therapeutics had a negative net margin of 146.86% and a negative return on equity of 112.95%. The business had revenue of $11.13 million during the quarter, compared to analyst estimates of $9.87 million. Sell-side analysts forecast that Capricor Therapeutics will post -1.21 EPS for the current year.

Institutional Investors Weigh In On Capricor Therapeutics

A number of institutional investors have recently made changes to their positions in the stock. Charles Schwab Investment Management Inc. increased its position in shares of Capricor Therapeutics by 51.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 111,336 shares of the biotechnology company’s stock valued at $1,536,000 after buying an additional 37,868 shares in the last quarter. Magnus Financial Group LLC bought a new position in Capricor Therapeutics in the fourth quarter valued at $276,000. JPMorgan Chase & Co. increased its position in shares of Capricor Therapeutics by 419.5% in the third quarter. JPMorgan Chase & Co. now owns 56,199 shares of the biotechnology company’s stock valued at $855,000 after acquiring an additional 45,381 shares during the last quarter. State Street Corp raised its holdings in Capricor Therapeutics by 27.8% during the third quarter. State Street Corp now owns 512,313 shares of the biotechnology company’s stock worth $7,792,000 after acquiring an additional 111,291 shares in the last quarter. Finally, Swiss National Bank bought a new stake in shares of Capricor Therapeutics during the 4th quarter worth approximately $930,000. 21.68% of the stock is owned by institutional investors and hedge funds.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.